WO2004043360A3 - Procedes d'utilisation de composes de vitamine d pour traiter des syndromes myelodysplasiques - Google Patents

Procedes d'utilisation de composes de vitamine d pour traiter des syndromes myelodysplasiques Download PDF

Info

Publication number
WO2004043360A3
WO2004043360A3 PCT/US2003/035244 US0335244W WO2004043360A3 WO 2004043360 A3 WO2004043360 A3 WO 2004043360A3 US 0335244 W US0335244 W US 0335244W WO 2004043360 A3 WO2004043360 A3 WO 2004043360A3
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
compounds
methods
treatment
myelodysplastic syndromes
Prior art date
Application number
PCT/US2003/035244
Other languages
English (en)
Other versions
WO2004043360A2 (fr
Inventor
Martha J Whitehouse
John G Curd
Original Assignee
Novacea Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacea Inc filed Critical Novacea Inc
Priority to MXPA05004985A priority Critical patent/MXPA05004985A/es
Priority to AU2003291294A priority patent/AU2003291294A1/en
Priority to EP03768685A priority patent/EP1562606A4/fr
Priority to JP2004551746A priority patent/JP2006508125A/ja
Priority to CA002505373A priority patent/CA2505373A1/fr
Publication of WO2004043360A2 publication Critical patent/WO2004043360A2/fr
Publication of WO2004043360A3 publication Critical patent/WO2004043360A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des procédés pour traiter des syndromes myélodysplasiques ou améliorer un symptôme de ceux-ci. Des procédés spécifiques consistent à administrer un ou plusieurs composés de vitamine D ou un sel, solvate, hydrate, stéréoisomère, clathrate ou promédicament de ceux-ci, acceptable d'un point de vue pharmaceutique, seuls ou associés à un ou plusieurs agents actifs supplémentaires. D'autres procédés consistent à administrer par intermittence une haute dose d'un ou de plusieurs composés de vitamine D ou d'un sel, solvate, hydrate, stéréoisomère, clathrate ou promédicament de ceux-ci, acceptable d'un point de vue pharmaceutique, seuls ou associés à un ou plusieurs agents actifs supplémentaires. Une telle administration par intermittence permet d'administrer de hautes doses de composés de vitamine D tout en minimisant ou supprimant l'apparition d'une hypercalcémie.
PCT/US2003/035244 2002-11-06 2003-11-06 Procedes d'utilisation de composes de vitamine d pour traiter des syndromes myelodysplasiques WO2004043360A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MXPA05004985A MXPA05004985A (es) 2002-11-06 2003-11-06 Metodos de uso de compuestos de vitamina d en el tratamiento de sindromes mielodisplasticos.
AU2003291294A AU2003291294A1 (en) 2002-11-06 2003-11-06 Methods of using vitamin d compounds in the treatment of myelodysplastic syndromes
EP03768685A EP1562606A4 (fr) 2002-11-06 2003-11-06 Procedes d'utilisation de composes de vitamine d pour traiter des syndromes myelodysplasiques
JP2004551746A JP2006508125A (ja) 2002-11-06 2003-11-06 骨髄異形成症候群の治療におけるビタミンｄ化合物の使用方法
CA002505373A CA2505373A1 (fr) 2002-11-06 2003-11-06 Procedes d'utilisation de composes de vitamine d pour traiter des syndromes myelodysplasiques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42454602P 2002-11-06 2002-11-06
US60/424,546 2002-11-06

Publications (2)

Publication Number Publication Date
WO2004043360A2 WO2004043360A2 (fr) 2004-05-27
WO2004043360A3 true WO2004043360A3 (fr) 2004-10-14

Family

ID=32312829

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/035244 WO2004043360A2 (fr) 2002-11-06 2003-11-06 Procedes d'utilisation de composes de vitamine d pour traiter des syndromes myelodysplasiques

Country Status (8)

Country Link
EP (1) EP1562606A4 (fr)
JP (1) JP2006508125A (fr)
KR (1) KR20050086545A (fr)
CN (1) CN100386083C (fr)
AU (1) AU2003291294A1 (fr)
CA (1) CA2505373A1 (fr)
MX (1) MXPA05004985A (fr)
WO (1) WO2004043360A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
AU2004247108A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc Treatment of immune-mediated disorders with active vitamin D compounds alone or in combination with other therapeutic agents
EP1791547A1 (fr) * 2004-05-28 2007-06-06 Abbott Laboratories Formulations orales de paricalcitol
WO2008097646A1 (fr) 2007-02-09 2008-08-14 Schering Corporation Procédés pour traiter et/ou prévenir la mucosite
JP5932339B2 (ja) * 2009-01-27 2016-06-08 バーグ エルエルシー 化学療法に付随する副作用を軽減するためのビタミンｄ３およびその類似体
CN103142478B (zh) * 2013-03-21 2014-10-01 青岛正大海尔制药有限公司 骨化三醇乳剂及其制备方法
CN109864992B (zh) * 2017-12-01 2021-07-27 暨南大学 维生素D3或其活性形式1α,25(OH)2D3在抑制PD-1表达中的应用
CN111228301A (zh) * 2020-01-14 2020-06-05 哈尔滨医科大学 一种用于治疗血管生成介导疾病的复方制剂及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521608B1 (en) * 1998-03-27 2003-02-18 Oregon Health & Science University Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009958A1 (en) * 1991-01-08 2004-01-15 Bone Care International, Inc. Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2
WO2003047595A1 (fr) * 2001-12-03 2003-06-12 Novacea, Inc. Compositions pharmaceutiques comprenant des composes actifs de vitamine d
JP2007501865A (ja) * 2003-06-11 2007-02-01 ノバセア インコーポレイティッド 放射線治療薬および放射線治療と併用した、活性ビタミンｄ化合物による癌の治療法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521608B1 (en) * 1998-03-27 2003-02-18 Oregon Health & Science University Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1562606A4 *

Also Published As

Publication number Publication date
CN1732009A (zh) 2006-02-08
JP2006508125A (ja) 2006-03-09
MXPA05004985A (es) 2005-08-02
EP1562606A2 (fr) 2005-08-17
EP1562606A4 (fr) 2006-05-24
AU2003291294A1 (en) 2004-06-03
KR20050086545A (ko) 2005-08-30
CA2505373A1 (fr) 2004-05-27
WO2004043360A2 (fr) 2004-05-27
CN100386083C (zh) 2008-05-07

Similar Documents

Publication Publication Date Title
AU2018256546A1 (en) Combination therapy with peptide epoxyketones
WO2005016326A3 (fr) Analogues de la thalidomide utilises comme inhibiteurs potentiels de l'angiogenese
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
HK1073427A1 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
WO2007038428A3 (fr) Prevention et traitement des troubles gastro-intestinaux et de la vessie lies a la chimiotherapie ou a la radio therapie a l'aide de composes actifs de vitamine d
WO2005070930A3 (fr) Composes de tetrahydrocarboline comme agents anticancereux
WO2005046318A3 (fr) Procedes d'utilisation et compositions comprenant des composes immunomodulatoires pour le traitement et la gestion de maladies et de troubles associe(e)s a l'amiante
WO2005044178A3 (fr) Procedes d'utilisation et compositions comprenant des composes immunomodulaires pour traiter, modifier et gerer la douleur
GB9902689D0 (en) Organic compounds
MX9203443A (es) Una forma de dosis para el suministro retardado de un farmaco.
WO2007062093A3 (fr) Polytherapie pour le traitement du cancer
TW200700093A (en) Pharmaceutical composition for the treatment of cancer
WO2004045593A3 (fr) Polytherapie anticancereuse au moyen d'un compose anticancereux active par gst et d'un autre traitement anticancereux
WO2004006859A3 (fr) Composes de platine
WO2005117542A3 (fr) Traitement du cancer du pancreas a l'aide de composes a base de vitamine d active, combine a d'autres traitements
HK1176318A1 (en) Injection device
TNSN07474A1 (en) Dosage regimen for prasugrel
WO2004043360A3 (fr) Procedes d'utilisation de composes de vitamine d pour traiter des syndromes myelodysplasiques
CA2595363A1 (fr) Methodes et mareriaux a base de trans-clomiphene permettant de traiter la sterilite masculine
CO6220945A2 (es) Uso de una composicion que comprende formoterol y dipropianato de beclometasona para la prevencion y/o tratamiento de una exacerbacion de asma
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
WO2004034962A3 (fr) Methode d'utilisation de medicaments selectifs inhibiteurs des cytokines et compositions comprenant des medicaments selectifs inhibiteurs des cytokines pour le traitement et la prise en charge de syndromes myelodysplasiques
WO2003007931A1 (fr) Derives de sulfonamide
WO2005120518A3 (fr) Utilisation d'analogues d'atp pour le traitement des maladies cardio-vasculaires
WO2001074365A3 (fr) Posologie efficace de galantamine reduisant les effets secondaires

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/004985

Country of ref document: MX

Ref document number: 2505373

Country of ref document: CA

Ref document number: 2004551746

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020057008448

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 540280

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003768685

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003291294

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20038A73796

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003768685

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057008448

Country of ref document: KR